AGYPHARMA LLC is organized around commercializing a novel and first-in-class bioprecursor prodrug of estradiol for the protection of the aging brain and eye. Preclinical studies have demonstrated that the intervention has the potential to treat various intractable medical conditions to include: Menopausal and climacteric symptoms; Neurodegenerative diseases, stroke and brain injury; Cognitive disorders associated with hormone deprivation; Retinal diseases associated with age-related macular degeneration, glaucoma and retinitis pigmentosa. AGYPHARMA is focuse around bridging the gap between academia and industry to advance therapeutics to the next level and/or to position the technology for acquisition by big pharma.
